

# Clinical trials of liraglutide other doses

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
<b>liraglutide other doses vs</b>			
<b>NN2211-1333</b> n=NA follow-up:	liraglutide versus placebo	obese subjects with type 2 diabetes	
<b>liraglutide other doses vs placebo</b>			
<b>Harder , 2004</b> n=21/12 follow-up: 8 weeks	single daily subcutaneous dose of 0.6 mg liraglutide for 8 weeks versus placebo	obese subjects with type 2 diabetes	Parallel groups double-blind Denmark
<b>Kaku 0.6mg , 2010</b> n=88/88 follow-up: 24 weeks	liraglutide 0.6 mg/day versus placebo	Japanese patients with type 2 diabetes	Parallel groups double-blind Japan
<b>Madsbad (vs placebo) , 2004</b> n=135/29 follow-up: 12 weeks	Liraglutide 0.045, 0.225, 0.45, 0.60, and 0.75 mg daily versus Placebo	Outpatients with type 2 diabetes	open UK, Scandinavia
<b>NN2211-1571 (Vilsbll) , 2007</b> [NCT00154401] n=123/40 follow-up: 14 weeks	liraglutide 0.65 mg, 1.25 mg or 1.9 mg for 14 weeks versus placebo	subjects with type 2 diabetes	Parallel groups double-blind Denmark, France, Slovakia, Netherlands
<b>Seino , 2008</b> [NCT00154414] n=180/46 follow-up: 14 weeks	Liraglutide 0.1, 0.3, 0.6 or 0.9 mg once daily for 14 weeks versus Placebo	Japanese subjects with type 2 diabetes	Parallel groups double blind Japan
<b>LIBRA ongoing</b> [NCT01270789] n=NA follow-up: 1 year	-	patients with T2DM	double-blind Canada

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>NCT00978393</b> <i>ongoing</i> [NCT00978393] n=NA follow-up:	High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg) s.c. once daily versus placebo	non-diabetic obese volunteers	double-blind Netherlands
<b>NN2211-1799</b> <i>ongoing</i> [NCT00620282] n=NA follow-up: 3 months	liraglutide Stepwise dose increase, s.c. injection, once daily versus placebo	subjects with type 2 diabetes who are on diet and lifestyle changes or treated with metformin alone	double-blind USA
<b>NN2211-1800</b> <i>ongoing</i> [NCT00943501] n=NA follow-up:	-	children with type 2 diabetes	double-blind USA, Europe
<b>NN2211-3619</b> <i>ongoing</i> [NCT01206101] n=NA follow-up:	-	Type 1 Diabetes Undergoing Islet Cell Transplantation	
<b>NN8022-1922</b> <i>ongoing</i> [NCT01272232] n=NA follow-up: 56 weeks	Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks in addition to subject's pre-trial background treatment versus placebo	overweight or obese subjects with type 2 diabetes	double-blind Africa, Asia, Europe and the United States of America
<b>NN8022-1923</b> <i>ongoing</i> [NCT00781937] n=NA follow-up: 56 weeks	Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen for subcutaneous (s.c.) injection, once daily versus placebo	obese non-diabetic subjects or overweight subjects who have medical problems such as hypertension or dyslipidaemia	double-blind North America
<b>liraglutide other doses vs placebo (add on MET)</b>			
<b>NN2211-1796</b> <i>unpublished</i> [NCT00614120] n=NA follow-up:	liraglutide added to metformin versus glimepiride added to metformin	-	China
<b>NCT01234649</b> <i>ongoing</i> [NCT01234649] n=NA follow-up:	addition of liraglutide to metformin versus metformin alone	at-risk overweight/obese women with prior gestational diabetes mellitus	double-blind USA
<b>liraglutide other doses vs placebo (on top SU)</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>Kaku 0.9mg , 2010</b> n=88/88 follow-up: 24 weeks	liraglutide 0.9 mg/day versus placebo	Japanese patients with type 2 diabetes	double-blind Japan
<b>liraglutide other doses vs placebo (add on SU)</b>			
<b>NN2211-1701 ongoing</b> [NCT00395746] n=NA follow-up: 24 weeks	liraglutide in combination with sulphonylurea versus placebo (add on to SU monotherapy)	subjects with type 2 diabetes	Parallel groups double-blind Japan
<b>liraglutide other doses vs sitagliptin (add on MET)</b>			
<b>MK-0431-403 ongoing</b> [NCT01296412] n=NA follow-up:	Liraglutide + metformin versus Sitagliptin + metformin	patients with Type 2 Diabetes that is not adequately controlled with metformin alone	parallel groups open
<b>liraglutide other doses vs glibenclamide</b>			
<b>Seino , 2010</b> [NCT00393718] n=272/139 follow-up: 24-week	liraglutide 0.9 mg once daily versus glibenclamide once or twice daily at a planned maximum dose of 2.5 mg/day, before or after meals	Japanese subjects with type 2 diabetes, inadequately controlled with diet therapy or oral antidiabetic drug monotherapy	Parallel groups double-blind Japan
<b>liraglutide other doses vs glimepiride</b>			
<b>Madsbad (vs Glimepiride) , 2004</b> n=135/26 follow-up: 12 weeks	Liraglutide 0.045, 0.225, 0.45, 0.60, and 0.75 mg daily versus Glimepiride	Outpatients with type 2 diabetes	Parallel groups open UK, Scandinavia
<b>liraglutide other doses vs metformin</b>			
<b>Feinglos , 2005</b> n=176/34 follow-up: 12 weeks	Liraglutide 0.045, 0.225, 0.45, 0.6 or 0.75 mg daily for 12 weeks versus metformin 1000mg twice daily	subjects with Type 2 diabetes	Parallel groups double blind (not adequate)
<b>liraglutide other doses vs rosiglitazone (add on SU)</b>			
<b>LEAD-1 SU (1.8 vs rosiglitazone) , 2009</b> [NCT00318422] n=228/232 follow-up: 26 weeks	Liraglutide 0.6, 1.2 or 1.8 mg daily versus rosiglitazone on-top of sulphonylureas		Parallel groups double-blind 21 countries
<b>liraglutide other doses vs insulin glargine</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
<b>EAGLE</b> <i>ongoing</i> [NCT01117350] n=NA follow-up:	Liraglutide (6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)) versus Insulin Glargine (100 Units/mL solution for injection in a pre-filled SoloStar pen)	Type 2 diabetic patients failing lifestyle management and oral agents	open USA

More details and results :

- insulin secretagogues peptides (incretins) for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q381>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/go-Q509>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled with insulin at <http://www.trialresultscenter.org/go-Q513>

## References

### NN2211-1333, :

Harder H, Nielsen L, Tu DT, Astrup A The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. *Diabetes Care* 2004;27:1915-21 [[15277417](#)]

### Harder, 2004:

Harder H, Nielsen L, Tu DT, Astrup A, The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. *Diabetes Care* 2004;27:1915-21. [[15277417](#)]

### Kaku 0.6mg, 2010:

Kaku K, Rasmussen MF, Clauson P, Seino Y Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. *Diabetes Obes Metab* 2010;12:341-7 [[20380655](#)] [10.1111/j.1463-1326.2009.01194.x](https://doi.org/10.1111/j.1463-1326.2009.01194.x)

### Madsbad (vs placebo), 2004:

Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. *Diabetes Care* 2004;27:1335-42 [[15161785](#)]

### NN2211-1571 (Vilsbll), 2007:

Vilsbll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrges JP, Verhoeven R, Bugnov I, Madsbad S Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. *Diabetes Care* 2007 Jun;30:1608-10 [[17372153](#)]

Courrges JP, Vilsbll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Bugov I, Madsbad S, Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. *Diabet Med* 2008;25:1129-31. [19183322] [10.1111/j.1464-5491.2008.02484.x](https://doi.org/10.1111/j.1464-5491.2008.02484.x)

Horowitz M, Vilsbll T, Zdravkovic M, Hammer M, Madsbad S, Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. *Diabetes Obes Metab* 2008;10:593-6. [18435773] [10.1111/j.1463-1326.2008.00861.x](https://doi.org/10.1111/j.1463-1326.2008.00861.x)

**Seino, 2008:**

Seino Y, Rasmussen MF, Zdravkovic M, Kaku K Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. *Diabetes Res Clin Pract* 2008;81:161-8 [18495285] [10.1016/j.diabres.2008.03.018](https://doi.org/10.1016/j.diabres.2008.03.018)

**LIBRA, 0:**

ongoing trial NCT01270789

**NCT00978393, 0:**

ongoing trial NCT00978393

**NN2211-1799, 0:**

ongoing trial NCT00620282

**NN2211-1800, 0:**

ongoing trial NCT00943501

**NN2211-3619, 0:**

ongoing trial NCT01206101

**NN8022-1922, 0:**

ongoing trial NCT01272232

**NN8022-1923, 0:**

ongoing trial NCT00781937

**NN2211-1796, 0:**

unpublished

Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbk N, Holst J, Nauck M Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. *J Clin Endocrinol Metab* 2011;96:1695-702 [21450987] [10.1210/jc.2010-2822](https://doi.org/10.1210/jc.2010-2822)

**NCT01234649, 0:**

ongoing trial NCT01234649

**Kaku 0.9mg, 2010:**

Kaku K, Rasmussen MF, Clauson P, Seino Y Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. *Diabetes Obes Metab* 2010;12:341-7 [20380655] [10.1111/j.1463-1326.2009.01194.x](https://doi.org/10.1111/j.1463-1326.2009.01194.x)

**NN2211-1701, 0:**

ongoing trial NCT00395746

Hegeds L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. *J Clin Endocrinol Metab*

2011;96:853-60 [[21209033](#)] [10.1210/jc.2010-2318](#)

**MK-0431-403, 0:**

ongoing trial NCT01296412

**Seino, 2010:**

Seino Y, Rasmussen MF, Nishida T, Kaku K, Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. *Curr Med Res Opin* 2010;26:1013-22. [[20199137](#)] [10.1185/03007991003672551](#)

**Madsbad (vs Glimepiride), 2004:**

Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. *Diabetes Care* 2004;27:1335-42 [[15161785](#)]

**Feinglos, 2005:**

Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. *Diabet Med* 2005;22:1016-23 [[16026367](#)] [10.1111/j.1464-5491.2005.01567.x](#)

**LEAD-1 SU (1.8 vs rosiglitazone), 2009:**

Marre M, Shaw J, Brndle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabet Med* 2009;26:268-78 [[19317822](#)] [10.1111/j.1464-5491.2009.02666.x](#)

**EAGLE, 0:**

ongoing trial NCT01117350

Entry terms: liraglutide, liraglutide, victoza